Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

PD-1–refractory advanced melanoma: how do we get to the finish line?

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma

Immunotherapy significantly increases the number of patients free from bowel cancer

Encouraging results using mismatched unrelated donors in stem cell transplantation

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Cancer advocacy and fundraising in Nigeria

ASCO 2024: Lung cancer roundup

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer